載入中
NASDAQHealthcareMedical - Devices
最新資料
US$0.132
+US$0.002 · +1.54%
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
前收盤價
US$0.132
+US$0.002 · +1.54%
盤前
US$0.1287
−US$0.0033 · -2.50%
10月13日 上午5:35 ET
盤中時間採用ET。市場資料可能有所延遲。
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
日內區間
目前US$0.132
52週區間
目前US$0.132
盤中時間採用ET。市場資料可能有所延遲。
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
日內區間
目前US$0.132
52週區間
目前US$0.132
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 26.9萬 USD | 30萬 USD | 18.9萬 USD | 27萬 USD |
| 銷貨成本 | 68.4萬 USD | 193.7萬 USD | 130.6萬 USD | 87.5萬 USD | 115.8萬 USD |
| 毛利 | −68.4萬 USD | −166.8萬 USD | −100.6萬 USD | −68.6萬 USD | −88.8萬 USD |
| 研究與開發 | 1063.9萬 USD | 463.4萬 USD | 1539.9萬 USD | 1785.5萬 USD | 1535.5萬 USD |
| 銷售、一般及管理費用 | 1056.7萬 USD | 697.6萬 USD | 1153.7萬 USD | 537.2萬 USD | 440.2萬 USD |
| 營業費用 | 2120.6萬 USD | 6081.2萬 USD | 2693.6萬 USD | 2322.7萬 USD | 1975.7萬 USD |
| 利息收入 | 47.7萬 USD | 42.3萬 USD | 3000 USD | 3.9萬 USD | 3000 USD |
| 利息支出 | 290.6萬 USD | −110.2萬 USD | 165.9萬 USD | 13.7萬 USD | — |
| 折舊和攤銷 | 97萬 USD | 138.6萬 USD | 53.2萬 USD | 49.5萬 USD | 33.6萬 USD |
| 營業利益 | −2189萬 USD | −6248萬 USD | −2794.2萬 USD | −2391.3萬 USD | −2064.5萬 USD |
| 淨利 | −2508.4萬 USD | −5376.3萬 USD | −3814.6萬 USD | −2367.3萬 USD | −1993.8萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$3.00
上漲空間 2172.73%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
